JPH0246599B2 - - Google Patents
Info
- Publication number
- JPH0246599B2 JPH0246599B2 JP1022771A JP2277189A JPH0246599B2 JP H0246599 B2 JPH0246599 B2 JP H0246599B2 JP 1022771 A JP1022771 A JP 1022771A JP 2277189 A JP2277189 A JP 2277189A JP H0246599 B2 JPH0246599 B2 JP H0246599B2
- Authority
- JP
- Japan
- Prior art keywords
- mta
- sulfoxide
- methylthioadenosine
- deoxy
- aggregation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WUUGFSXJNOTRMR-UHFFFAOYSA-N 5alpha-Hydroxy-3abeta,5beta,8-trimethyl-1-(1,5-dimethyl-hexen-(4)-yl)-4abetaH,7abetaH-dicyclopentano[a.d]cyclooctaen-(8) Natural products OC1C(O)C(CSC)OC1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-UHFFFAOYSA-N 0.000 claims description 51
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 claims description 46
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 15
- 229960001570 ademetionine Drugs 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 150000003462 sulfoxides Chemical class 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 19
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 11
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 10
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- -1 MTA sulfoxide Chemical class 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 230000002744 anti-aggregatory effect Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 230000001754 anti-pyretic effect Effects 0.000 description 5
- 231100001274 therapeutic index Toxicity 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- IYSNPOMTKFZDHZ-KQYNXXCUSA-N 5'-chloro-5'-deoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CCl)[C@@H](O)[C@H]1O IYSNPOMTKFZDHZ-KQYNXXCUSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229960000212 aminophenazone Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- WXOJULRVRHWMGT-JLQSGANNSA-N 5'-deoxy-5'-(methylsulfinyl)adenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CS(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WXOJULRVRHWMGT-JLQSGANNSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- IOYQOOUTHXXDIC-UHFFFAOYSA-N CSc1cccc(CC(C)N)c1 Chemical compound CSc1cccc(CC(C)N)c1 IOYQOOUTHXXDIC-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT21550/80A IT1193529B (it) | 1980-04-22 | 1980-04-22 | Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo |
IT21550A/80 | 1980-04-22 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5930181A Division JPS56166117A (en) | 1980-04-22 | 1981-04-21 | Antiinflammatory and analgesic adenosine derivative and therapeutical composition containing it as effective component |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01301692A JPH01301692A (ja) | 1989-12-05 |
JPH0246599B2 true JPH0246599B2 (US20020051482A1-20020502-M00012.png) | 1990-10-16 |
Family
ID=11183457
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5930181A Granted JPS56166117A (en) | 1980-04-22 | 1981-04-21 | Antiinflammatory and analgesic adenosine derivative and therapeutical composition containing it as effective component |
JP1022771A Granted JPH01301692A (ja) | 1980-04-22 | 1989-02-02 | 5’―デオキシ―5’―メチルチオアデノシンの新規な製造方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5930181A Granted JPS56166117A (en) | 1980-04-22 | 1981-04-21 | Antiinflammatory and analgesic adenosine derivative and therapeutical composition containing it as effective component |
Country Status (17)
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1177373B (it) * | 1984-12-06 | 1987-08-26 | Bioresearch Spa | Sali della 5'-metiltio-5'-deossiadenosina con acidi solfonici a lunga catena alchilica |
IT1227049B (it) * | 1988-07-29 | 1991-03-14 | Bioresearch Spa | Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante. |
JPH0497287A (ja) * | 1990-08-10 | 1992-03-30 | Nec Ic Microcomput Syst Ltd | 画像表示集積回路 |
EP1891961B1 (en) * | 2005-03-17 | 2009-09-16 | Proyecto de Biomedicina Cima, S.L. | Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection |
ES2259552B1 (es) * | 2005-03-17 | 2007-06-16 | Proyecto De Biomedicina Cima, S.L. | Empleo de 5'-metiltioadenosina (mta) en la prevencion y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes. |
DE102010027595A1 (de) * | 2010-07-23 | 2012-01-26 | Helmut Vorbrüggen | Vermeidung von Ischämie- oder Degenerations-Schäden im Gehirn bei Anwendung von Adenosin-Derivaten |
DE102011005232A1 (de) * | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
WO2014163151A1 (ja) * | 2013-04-05 | 2014-10-09 | ライオン株式会社 | 酵母培養物及び内服組成物 |
WO2014163150A1 (ja) * | 2013-04-05 | 2014-10-09 | ライオン株式会社 | 内服組成物 |
WO2014163152A1 (ja) * | 2013-04-05 | 2014-10-09 | ライオン株式会社 | ノンレム睡眠促進剤、深睡眠促進剤および自然睡眠誘発剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1259341B (de) * | 1962-12-22 | 1968-01-25 | Boehringer & Soehne Gmbh | Verfahren zur Herstellung neuer 5'-Sulfoxyde von Nucleosiden |
DE1545645A1 (de) * | 1965-12-06 | 1969-08-21 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von disubstituierten Adenosin-Derivaten |
GB1436509A (en) * | 1973-11-27 | 1976-05-19 | Ajinomoto Kk | Method for producing s-adenosylmethionine or methylthioadenosine from yeast |
FR2313937A1 (fr) * | 1975-06-09 | 1977-01-07 | Anvar | Medicament a base de 5' thioethers de l'adenosine |
FR2424027A1 (fr) * | 1978-04-28 | 1979-11-23 | Merieux Inst | Nouveau medicament, notamment sedatif et inducteur de sommeil et compositions pharmaceutiques la renfermant |
-
1980
- 1980-04-22 IT IT21550/80A patent/IT1193529B/it active
-
1981
- 1981-04-17 BE BE0/204529A patent/BE888472A/fr not_active IP Right Cessation
- 1981-04-21 SE SE8102489A patent/SE460198B/sv not_active IP Right Cessation
- 1981-04-21 CA CA000375784A patent/CA1198105A/en not_active Expired
- 1981-04-21 LU LU83307A patent/LU83307A1/fr unknown
- 1981-04-21 AR AR285020A patent/AR231144A1/es active
- 1981-04-21 NO NO811346A patent/NO150515C/no unknown
- 1981-04-21 JP JP5930181A patent/JPS56166117A/ja active Granted
- 1981-04-21 ES ES501539A patent/ES501539A0/es active Granted
- 1981-04-21 DK DK176481A patent/DK159453C/da not_active IP Right Cessation
- 1981-04-22 GB GB8112428A patent/GB2074446B/en not_active Expired
- 1981-04-22 CH CH4716/84A patent/CH650514A5/de not_active IP Right Cessation
- 1981-04-22 FI FI811249A patent/FI70227C/fi not_active IP Right Cessation
- 1981-04-22 DE DE19813116067 patent/DE3116067A1/de active Granted
- 1981-04-22 NL NL8101984A patent/NL192111C/nl not_active IP Right Cessation
- 1981-04-22 CH CH263281A patent/CH645544A5/de not_active IP Right Cessation
- 1981-04-22 FR FR8107992A patent/FR2491761A1/fr active Granted
-
1982
- 1982-04-01 ES ES511039A patent/ES8306378A1/es not_active Expired
-
1983
- 1983-08-15 GB GB08321947A patent/GB2144409B/en not_active Expired
-
1984
- 1984-05-25 GB GB08413454A patent/GB2144038B/en not_active Expired
-
1987
- 1987-03-04 SE SE8700914A patent/SE464635B/sv not_active IP Right Cessation
- 1987-03-04 SE SE8700913A patent/SE466238B/sv not_active IP Right Cessation
-
1989
- 1989-02-02 JP JP1022771A patent/JPH01301692A/ja active Granted
-
1992
- 1992-06-26 MX MX9203630A patent/MX9203630A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2186792B1 (en) | 2-(a-hydroxypentyl) benzoate and its preparation and use | |
EP0025692B1 (en) | Quinone derivatives, their production and use | |
RU2144027C1 (ru) | Изохинолины, способ их получения и фармацевтическая композиция на их основе | |
US4454122A (en) | Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle | |
JPH03148219A (ja) | 膜安定化剤 | |
JPH0246599B2 (US20020051482A1-20020502-M00012.png) | ||
US4373097A (en) | Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity | |
IE851188L (en) | Sulphoadenosylmethionine salts | |
JPH024235B2 (US20020051482A1-20020502-M00012.png) | ||
MXPA06005894A (es) | Inhibidores de comt. | |
US4096252A (en) | 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents | |
US4973678A (en) | Salts of 5'-methylthio-5'-deoxyadenosine with long-alkyl chain sulphonic acids | |
US4694018A (en) | Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives | |
JPH05247078A (ja) | 糖化合物、シアル酸含有糖鎖類生合成阻害剤、その製造方法、並びに新規な中間体 | |
CA2044125A1 (en) | Anti-hbv pyrimidine nucleoside | |
WO1990013557A1 (en) | New s-adenosylmethionine derivative | |
CA1209915A (en) | Adenosine derivatives of antiinflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle | |
AU2019254962C1 (en) | Isoindole derivatives | |
Anderson et al. | THE CHEMISTRY OF THE LIPOIDS OF TUBERCLE BACILLI. XIII. THE OCCURRENCE OF MANNOSE IN THE PHOSPHATIDE FROM HUMAN TUBERCLE BACILLI1 | |
JPH0321535B2 (US20020051482A1-20020502-M00012.png) | ||
JP3578412B2 (ja) | 新規なベンズアニリド型化合物及び血行促進のために使用する医薬 | |
EP0006784B1 (fr) | Nouveaux dérivés de la L-cystéine et leur application comme médicament, ainsi que procédé pour leur préparation | |
WO1995030683A1 (en) | Adenosine derivatives | |
JPS59104358A (ja) | 1α,24−ジヒドロキシコレカルシフエロ−ルの一水塩及びその製造法 | |
JPS6361299B2 (US20020051482A1-20020502-M00012.png) |